Mark Murcko has made significant contributions to drug discovery, being directly involved in the development of nine marketed drugs and several molecules in clinical trials. He is currently a board member and interim chief scientific officer at Dewpoint Therapeutics and a senior lecturer in the Department of Biological Engineering at MIT. Throughout his career, he has been a co-inventor on numerous patents and has delivered numerous scientific lectures and authored scientific articles.